Mangoceuticals, Inc. (MGRX) Key Metrics
MGRX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $6.4M
- Enterprise value
- $9.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 20.4
- Price / book
- 0.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.98
MGRX key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMGRX returns How much profit the business earns on the capital it uses.
MGRX financial health Debt, liquidity and how easily interest is covered.
MGRX efficiency & capital use Working capital cycle and where the cash goes.
MGRX valuation history
MGRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MGRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MGRX cash returned to shareholders
MGRX price vs earnings per share
MGRX key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $7.5M | — | — | — | — |
| Enterprise value | $6.3M | — | — | — | — |
| Price / sales | 16.3 | — | — | — | — |
| Price / book | 0.5 | — | — | — | — |
| EV / sales | 13.8 | — | — | — | — |
| Earnings yield | −277.0% | — | — | — | — |
| Free cash flow yield | −78.5% | — | — | — | — |
| Share price at fiscal year-end | $0.74 | $2.42 | $4.16 | — | — |
| Per share | |||||
| Revenue per share | $0.05 | — | — | — | — |
| Earnings per share | −$2.05 | — | — | — | — |
| Operating cash flow per share | −$0.58 | — | — | — | — |
| Free cash flow per share | −$0.58 | — | — | — | — |
| Cash per share | $0.15 | — | — | — | — |
| Book value per share | $1.51 | — | — | — | — |
| Tangible book value per share | $0.10 | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — |
| Debt per share | $0.03 | — | — | — | — |
| Shares outstanding | 10.1M | — | — | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −141.7% | −118.3% | — | −669.0% | — |
| Return on invested capital (ROIC) | −107.6% | −88.3% | — | — | — |
| Return on assets (ROA) | −131.2% | −106.0% | −897.0% | −389.5% | −78.5% |
| Return on tangible assets | — | — | −876.7% | −199.2% | −78.5% |
| Free cash flow margin | — | −789.7% | −957.1% | — | — |
| Financial health | |||||
| Total debt | $307,823 | $214,962 | $128,679 | $352,865 | $39,270 |
| Cash & short-term investments | $1.5M | $58,653 | $739,006 | $682,860 | $22,550 |
| Net debt | −$1.2M | $156,309 | −$610,327 | −$329,995 | $16,720 |
| Debt / equity | 0.02 | 0.02 | 0.17 | 0.57 | — |
| Debt / assets | 0.02 | 0.01 | 0.12 | 0.35 | 1.74 |
| Current ratio | 1.74 | 0.05 | 3.88 | 2.67 | 0.57 |
| Quick ratio | 1.74 | 0.05 | 3.79 | 2.67 | 0.57 |
| Interest coverage | -185.0 | -581.9 | — | -307.7 | -96.8 |
| Working capital | $656,866 | −$1.3M | $607,382 | $434,028 | −$16,720 |
| Invested capital | $14.0M | $14.1M | $164,427 | $284,035 | $0 |
| Tangible asset value | $966,521 | −$1.3M | $774,754 | $614,030 | −$16,720 |
| Net current asset value | $656,866 | −$1.3M | $542,421 | $305,348 | −$16,720 |
| Graham net-net per share | $0.06 | — | — | — | — |
| Capital allocation | |||||
| Dividends paid | — | $802,109 | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.5% | 482.2% | — |
| Capex / depreciation | 0.00 | 0.00 | 0.14 | 11.16 | 11.16 |
| Stock-based compensation / revenue | 256.2% | 40.4% | 85.4% | 2,618.7% | — |
| SG&A / revenue | 3,666.8% | 1,282.4% | 740.5% | 22,334.0% | — |
| Efficiency | |||||
| Days sales outstanding | — | — | 0.0 | — | — |
| Days of inventory on hand | — | — | 11.3 | — | — |
| Days payables outstanding | 1,113.1 | 756.8 | 106.1 | 3,006.0 | — |
| Cash conversion cycle (days) | — | — | -94.9 | — | — |
| Payables turnover | 0.33 | 0.48 | 3.44 | 0.12 | — |
| Inventory turnover | — | — | 32.43 | — | — |
| Asset turnover | 0.03 | 0.08 | 0.71 | 0.02 | 0.00 |
| Average receivables | — | — | $0 | — | — |
| Average payables | $627,092 | $489,133 | $87,220 | $33,675 | — |
| Average inventory | — | $9,250 | $9,250 | $0 | — |
| Intangibles / total assets | 88.5% | 99.1% | 0.0% | 0.0% | 0.0% |
Computed from MGRX's annual financial statements (latest annual report filed April 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MGRX valuation and financial ratios
Mangoceuticals earned a return on equity of −141.7% and a return on invested capital of −107.6% in fiscal 2025. It ended the year with $0.3 million of debt and $1.5 million in cash and short-term investments, a net cash position of $1.2 million.
See the MGRX income statement, the MGRX chart for price history, or the MGRX stock overview for the latest quote and news.
MGRX key metrics FAQ
What is Mangoceuticals's return on equity?
Mangoceuticals's return on equity (ROE) was −141.7% in fiscal 2025: net income of -$20.6 million on average shareholders' equity of $14.6 million.
What is Mangoceuticals's ROIC?
Mangoceuticals's return on invested capital was −107.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Mangoceuticals have?
Mangoceuticals had total debt of $0.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Mangoceuticals's free cash flow yield?
Mangoceuticals generated -$5.9 million of free cash flow in fiscal 2025, a free cash flow yield of −78.5% on its market value at year-end ($7.5 million).
What is Mangoceuticals's current ratio?
Mangoceuticals's current ratio was 1.74 at the end of fiscal 2025: current assets were 1.74 times current liabilities.